Development and validation of a bedside score to predict early death in cancer of unknown primary patients.

<h4>Background</h4>We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients.<h4>Methods</h4>Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising...

Full description

Bibliographic Details
Main Authors: Nicolas Penel, Sylvie Negrier, Isabelle Ray-Coquard, Charles Ferte, Patrick Devos, Antoine Hollebecque, Michael B Sawyer, Antoine Adenis, Pascal Seve
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-08-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19649260/?tool=EBI
Description
Summary:<h4>Background</h4>We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients.<h4>Methods</h4>Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors for each patient (0 to 4).<h4>Results</h4>The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-day-mortality: performance status>1 (OR = 3.03, p = 0.001), at least one co-morbidity requiring treatment (OR = 2.68, p = 0.004), LDH>1.5 x the upper limit of normal (OR = 2.88, p = 0.007) and low albumin or protein levels (OR = 3.05, p = 0.007). In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0-1], 2 and [3]-[4], respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values.<h4>Conclusions</h4>We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather than aggressive chemotherapy.
ISSN:1932-6203